Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia

Potential of Inaccurate Cefiderocol Susceptibility Results: a CLSI AST Subcommittee Advisory

(2023) Patricia J. Simner et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study

(2023) Jinnethe Reyes et al.   Lancet Microbe

Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018–2021

(2023) Yu-Lin Lee et al.   JOURNAL OF INFECTION

Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins

(2021) Florian Wagenlehner et al.   CLINICAL MICROBIOLOGY AND INFECTION

Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa

(2020) Bartolome Moya et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems

(2020) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of cefiderocol, a siderophore-cephalosporin, against multidrug-resistant gram-negative bacteria

(2020) Shazad Mushtaq et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

(2019) Brian T. Tsuji et al.   PHARMACOTHERAPY

Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model

(2019) James M Kidd et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa

(2019) Elias M. Mullane et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

(2018) Mical Paul et al.   LANCET INFECTIOUS DISEASES

Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae

(2017) Aurélie Jayol et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria

(2017) David M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY